Asunto(s)
Anticuerpos Monoclonales Humanizados/administración & dosificación , Cloroquina/administración & dosificación , Infecciones por Coronavirus/tratamiento farmacológico , Citocinas/metabolismo , Progresión de la Enfermedad , Neumonía Viral/tratamiento farmacológico , Resultado del Tratamiento , COVID-19 , Prueba de COVID-19 , Técnicas de Laboratorio Clínico , Infecciones por Coronavirus/diagnóstico , Quimioterapia Combinada , Hospitalización , Humanos , Tiempo de Internación , Masculino , Persona de Mediana Edad , Pandemias , Neumonía Viral/diagnóstico , Medición de Riesgo , Índice de Severidad de la Enfermedad , Tratamiento Farmacológico de COVID-19RESUMEN
OBJECTIVE: The long non-coding ribonucleic acid (lncRNA)-myocardial infarction associated transcript (MIAT) has been demonstrated to serve as a key regulator in various physiological and pathological processes. This study aims to explore whether lncRNA-MIAT regulates the expression of micro RNA (miR)-29a to affect kidney's injury in sepsis rats. MATERIALS AND METHODS: A total of 30 healthy male Sprague-Dawley (SD) rats were randomly divided into experimental group and control group. Rats in the experimental group were injected with lipopolysaccharide (LPS) through the tail vein to prepare the model of sepsis-induced kidney injury, while those in the control group with the equal volume of normal saline. After the levels of serum creatinine (SCr) and blood urea nitrogen (BUN) in rats were determined to ascertain successful modeling, fluorescence quantitative Real-time polymerase chain reaction (qRT-PCR) was performed to measure the expression levels of the lncRNA-MIAT and miR-29a messenger RNAs (mRNAs) in renal tissues. The normal rat kidney epithelial (NRK-52E) cell line was cultured in vitro, and the model was established in vitro via LPS to study the influences of lncRNA-MIAT and miR-29a on the kidney injury in sepsis rats. Moreover, cell apoptosis was detected using Western blotting. RESULTS: According to the results of the rat in vivo experiment and NRK-52E cell line in vitro experiment, the model of kidney injury was established successfully, and compared with the control group, experiment group had significantly raised SCr and BUN levels (p<0.01) and a remarkably increased lincRNA-MIAT gene expression level (p<0.01), but a substantially decreased miR-29a gene expression level (p<0.01). Additionally, when the expression of lncRNA-MIAT was up-regulated, the expression of miR-29a was prominently decreased (p<0.01), but that of the cell apoptosis gene cysteine-aspartic proteases (Caspase)-8 protein was remarkably increased (p<0.01). However, the expression of Caspase-8 protein was significantly lowered (p<0.01) once the expression of miR-29a was up-regulated. CONCLUSIONS: LncRNA-MIAT may bind to miR-29a to participate in sepsis-related kidney injury.
Asunto(s)
Lesión Renal Aguda/metabolismo , MicroARNs/genética , ARN Largo no Codificante/metabolismo , Sepsis/metabolismo , Lesión Renal Aguda/inducido químicamente , Lesión Renal Aguda/patología , Animales , Apoptosis , Células Cultivadas , Modelos Animales de Enfermedad , Inyecciones Intravenosas , Lipopolisacáridos/administración & dosificación , Masculino , MicroARNs/análisis , MicroARNs/metabolismo , ARN Largo no Codificante/genética , Ratas , Ratas Sprague-Dawley , Sepsis/inducido químicamente , Sepsis/patologíaRESUMEN
Glioma is one of the most commonly malignant brain tumors. Current therapies for glioma have failed to achieve satisfactory results, which necessitates the development of novel molecular therapies. In the current study, we aimed to investigate the role of NUF2 (Ndc80 kinetochore complex component) in glioma cell growth and assessed the possible mechanisms underlying NUF2-mediated glioma development. The lentivirus-based short hairpin RNA-expressing vectors were constructed and transfected into U87 and U251 cells. Real time PCR and western blot were performed for expression level determination. Annexin V-FITC/PI flow cytometric assay was conducted to determine apoptotic cell proportions. Cell viability in vitro and tumorgenic ability in vivo were assessed by MTT assay and a nude mouse xenograft, respectively. We found that NUF2 was overexpressed in glioma tissues and differentially expressed in a series of glioma cell lines. Depletion of NUF2 by short-hairpin RNA inhibited cell growth in vitro and in vivo. Furthermore, NUF2 depletion-induced growth inhibition was associated with cell cycle arrest and apoptosis. Aberrant expressions of cell cycle regulators and apoptosis-related proteins further confirmed that NUF2 depletion induced cell cycle arrest and apoptosis. In all, our results indicate that siRNA-mediated knockdown against NUF2 may be a promising therapeutic method for the treatment of glioma.
Asunto(s)
Neoplasias Encefálicas/patología , Neoplasias Encefálicas/terapia , Proteínas de Ciclo Celular/genética , Glioma/patología , Glioma/terapia , ARN Interferente Pequeño/uso terapéutico , Animales , Apoptosis , Encéfalo/metabolismo , Encéfalo/patología , Neoplasias Encefálicas/genética , Línea Celular Tumoral , Regulación Neoplásica de la Expresión Génica , Glioma/genética , Humanos , Ratones , Ratones Desnudos , Interferencia de ARN , ARN Interferente Pequeño/genéticaRESUMEN
Osteosarcoma is the most common type of bone cancer, with a peak incidence in the early childhood. The relationship between microRNAs (miRNAs) and cancer development attracted more and more attention over the last few years. Members of the miRNA-29 family, including miRNA-29a, miRNA-29b, and miRNA-29c were shown to participate in the development of rhabdomyosarcoma and hepatocarcinogenesis. Here, it has been demonstrated miRNA-29a and miRNA-29b expression levels to be downregulated in most of the osteosarcoma tissues (23 from 30). Besides, miRNA-29a displayed ability to induce apoptosis in both U2OS and SAOS-2 osteoblastic cells. While miRNA-29 members induced apoptosis through p53 gene activation, the effect of miRNA-29a on osteoblastic cells was independent on p53 expression level. Moreover, Bcl-2 and Mcl-1 were earlier demonstrated to be the direct targets of miRNA-29 in many types of cancer tissues and cancers. In both U2OS and SAOS-2 osteoblastic cell types, overexpression of miRNA-29a also downregulated Bcl-2 and Mcl-1, while silencing of miRNA-29a increased their expression. In addition, enhanced expression of miRNA-29a increased the expression of two tumor suppressor genes, E2F1 and E2F3. In summary, data obtained highlight the role of miRNA-29a in the regulation of osteoblastic cell apoptosis by silencing Bcl-2 and Mcl-1 and inducing E2F1 and E2F3 expression.
Asunto(s)
Neoplasias Óseas/genética , MicroARNs/genética , Osteoblastos/metabolismo , Osteosarcoma/genética , Apoptosis/genética , Neoplasias Óseas/patología , Neoplasias Óseas/fisiopatología , Línea Celular Tumoral , Transformación Celular Neoplásica , Progresión de la Enfermedad , Regulación hacia Abajo , Factor de Transcripción E2F1/metabolismo , Factor de Transcripción E2F3/metabolismo , Regulación Neoplásica de la Expresión Génica , Genes p53/genética , Humanos , Proteína 1 de la Secuencia de Leucemia de Células Mieloides , Osteoblastos/patología , Osteosarcoma/patología , Osteosarcoma/fisiopatología , Proteínas Proto-Oncogénicas c-bcl-2/genética , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Transgenes/genéticaRESUMEN
We have previously demonstrated a significant inverse correlation between circulating thrombopoietin (TPO) levels and peripheral platelet (PLT) counts in patients with thrombocytopenia secondary to megakaryocytic hypoplasia but not in patients with immune thrombocytopenic purpura (ITP; Chang et al, Blood 88:3354, 1996). To test the hypothesis that the differences in the circulating TPO levels in these two types of thrombocytopenia are caused by differences in the total capacity of Mpl receptor-mediated TPO clearance, thrombocytopenia was induced in female CD-1 mice either by sublethal irradiation (irradiated) or rabbit antimouse PLT serum (RAMPS) for 1 day (1 d RAMPS) and 5 days (5 d RAMPS). A well-characterized murine model of autoimmune thrombocytopenic purpura, male (NZW x BXSB) F1 mice (W/B F1), was also included in this study. All thrombocytopenic mice and their controls received trace amounts of 125I-recombinant murine TPO (125I-rmTPO) intravenously and were killed 3 hours postinjection. Blood cell-associated radioactivity was significantly decreased in all 4 groups of thrombocytopenic mice. Significantly increased plasma and decreased whole spleen-associated radioactivity was observed in the irradiated group compared with controls (P <.05). While a lesser but still significant increase in plasma and decrease in whole spleen-associated radioactivity was observed in the 1 d RAMPS mice (P <.05), there were no significant differences between the 5 d RAMPS nor the W/B F1 male mice compared with controls, although whole spleen-associated radioactivity was higher in the W/B F1 male. A significant inverse correlation of plasma and whole spleen-associated radioactivity was demonstrated in W/B F1 male mice (r = -.91, n = 6, P <.05). There was also a decrease in bone (femur)/blood-associated radioactivity in the irradiated group compared with controls (P <.05), but a significant increase in 1 d and 5 d RAMPS mice (P <.01). Furthermore, the 125I-rmTPO uptake capacity within the spleen and marrow of immune thrombocytopenic mice appeared to be associated with a higher megakaryocytic mass when tissue samples were examined by light microscopy. Internalization of 125I-rmTPO by megakaryocytes and PLTs in the spleens and marrows of ITP mice was also demonstrated directly using electron microscopic autoradiography. Labeled PLTs were also found within splenic macrophages. Additionally, the mean PLT volumes of RAMPS mice were significantly higher than those of the control and irradiated mice (P <.05), as was the bound 125I-rmTPO (cpm) per million PLT (P <.05). Finally, significantly decreased 125I-rmTPO degradation products were only found in the plasma of the irradiated mice compared with control animals (P <.05). These data suggest that the lack of Mpl+ cells in the mice with thrombocytopenia secondary to megakaryocytic hypoplasia (irradiated) results in decreased uptake and degradation of TPO and higher circulating TPO levels. Furthermore, these data also suggest that, after a brief TPO surge in response to immune thrombocytopenia (1 d RAMPS), the lack of an inverse correlation of circulating TPO with PLT counts during steady-state immune thrombocytopenic mice (5 d RAMPS + W/B F1 male) is due, at least in part, to its uptake and degradation by the high PLT turnover and increased mass of megakaryocytes.
Asunto(s)
Púrpura Trombocitopénica Trombótica/sangre , Trombocitopenia/sangre , Trombopoyetina/farmacocinética , Animales , Femenino , Sueros Inmunes , Radioisótopos de Yodo , Masculino , Megacariocitos/metabolismo , Ratones , Ratones Endogámicos , Recuento de Plaquetas , Púrpura Trombocitopénica Trombótica/genética , Conejos , Proteínas Recombinantes/sangre , Proteínas Recombinantes/farmacocinética , Trombopoyetina/sangre , Factores de Tiempo , Distribución Tisular , Irradiación Corporal TotalRESUMEN
Two single-center, open-label studies examined the potential effects of tiagabine on the pharmacokinetics and safety of carbamazepine and phenytoin at steady state. Twelve adult patients with seizures controlled by an individualized fixed dosage of antiepilepsy medication (carbamazepine or phenytoin) participated in each study. On day 1, the pharmacokinetics of the baseline antiepilepsy drug were determined. On days 2 through 18, tiagabine was titrated from 8 to 48 mg/d (or the maximum tolerated dose up to 48 mg/d), and the usual fixed dosage of carbamazepine or phenytoin was continued. The pharmacokinetic assessment was repeated on day 18. There were no statistically significant differences in carbamazepine, carbamazepine epoxide, and phenytoin pharmacokinetic parameters when either drug was administered alone or in combination with tiagabine. In each study, 11 of 12 patients (92%) experienced treatment-emergent adverse events after tiagabine was added. The most frequent adverse events were dizziness, headache, difficulty concentrating, drowsiness, and tremor. Most symptoms were mild or moderate in severity and resolved without further treatment, although tiagabine dosage reductions were required by 4 patients in the carbamazepine study and by 3 patients in the phenytoin study. There were no clinically important effects on physical examination or neurologic test results, laboratory values, or vital signs. The results suggest that addition of tiagabine to a fixed regimen of either carbamazepine or phenytoin is generally well tolerated and that carbamazepine and phenytoin steady-state pharmacokinetics are unaffected by the addition of tiagabine.
Asunto(s)
Anticonvulsivantes/administración & dosificación , Anticonvulsivantes/farmacocinética , Carbamazepina/farmacocinética , Agonistas del GABA/administración & dosificación , Agonistas del GABA/farmacocinética , Ácidos Nipecóticos/administración & dosificación , Ácidos Nipecóticos/farmacocinética , Fenitoína/farmacocinética , Convulsiones/tratamiento farmacológico , Adolescente , Adulto , Anticonvulsivantes/sangre , Carbamazepina/sangre , Mareo/inducido químicamente , Interacciones Farmacológicas , Monitoreo de Drogas , Quimioterapia Combinada , Femenino , Agonistas del GABA/sangre , Cefalea/inducido químicamente , Humanos , Masculino , Persona de Mediana Edad , Ácidos Nipecóticos/sangre , Fenitoína/sangre , Convulsiones/sangre , Fases del Sueño/efectos de los fármacos , Tiagabina , Temblor/inducido químicamenteRESUMEN
Interleukin-15 (IL-15) is an important lymphokine regulating natural killer (NK) activity, T-cell proliferation, and T-cell cytotoxic activities. We hypothesized that the reduced expression and production of IL-15 from cord blood (CB) may contribute to the immaturity of CB immunity and potentially delay immune reconstitution after CB transplantation. We compared the expression and production of IL-15 from activated cord versus adult mononuclear cells (MNCs) and the regulatory mechanisms associated with IL-15 expression in CB MNCs. We have also studied the effect of exogenous IL-15 stimulation on CB and adult peripheral blood (APB) MNCs in terms of NK and lymphokine-activated killer (LAK) activities and cytokine induction. Lipopolysaccharide (LPS)-stimulated CB and APB MNCs were used to determine IL-15 expression and protein production by Northern analysis and Western immunoblot analysis. IL-15 mRNA expression and protein accumulation in CB MNC were 25% +/- 2.0% (12 hours, n = 4, P < .05) and 30% +/- 2.5% (12 hours, n = 3, P < .05), respectively, when compared with APB MNCs. Nuclear run-on assays showed no differences between CB and APB MNCs during basal levels of transcription and after transcriptional activation. However, the half-life of IL-15 mRNA was approximately twofold lower in activated CB MNCs than in activated APB MNCs (CB: 101 +/- 5.8 minutes v APB: 210 +/- 8.2 minutes, n = 3, P < .05). Exogenous IL-15 significantly enhanced CB NK and LAK activities up to comparable levels of APB (P < .05). IL-15 also significantly induced interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha) protein production (days 1, 3, and 6, P < .05, n = 3) in CB MNCs. IL-15-stimulated LAK cells induced a significant lytic response against two acute lymphoblastic cell lines and two pediatric neuroblastoma cell lines. Both NK and LAK activities were augmented by the combination of IL-12 and IL-15, and the low-dose combination of IL-12 and IL-15 achieved similar levels of in vitro NK and LAK cytotoxicity compared with higher doses of either lymphokine. The present study suggests that IL-15 mRNA and protein expression is decreased in activated CB, secondary, in part, to altered posttranscriptional regulation. The reduced production of IL-15 from CB MNCs in response to stimulation may contribute to the decrease in IFN-gamma and TNF-alpha production and CB cellular immunity. However, exogenous IL-15 enhanced IFN-gamma and TNF-alpha production and NK and LAK cytotoxicities in CB MNCs. The reduced production of IL-15 from activated CB may contribute to the immaturity of CB cellular immunity and delayed immune reconstitution after unrelated CB transplantation. Exogenous IL-15 administration may compensate for the immaturity of CB immunity. The synergistic in vitro effects of low-dose IL-12 and IL-15 also implies the possible use of low doses each of IL-12 and IL-15 for enhancing immune reconstitution and/or possibly as a form of antitumor immunotherapy after CB transplantation.
Asunto(s)
Citocinas/biosíntesis , Sangre Fetal/química , Inmunidad Celular , Interleucina-15/sangre , Leucocitos Mononucleares/química , Regulación hacia Arriba , Adulto , Citocinas/sangre , Citotoxicidad Inmunológica/efectos de los fármacos , Sinergismo Farmacológico , Humanos , Interferón gamma/sangre , Interleucina-12/farmacología , Interleucina-15/genética , Interleucina-15/farmacología , Células Asesinas Activadas por Linfocinas/inmunología , Células Asesinas Naturales/inmunología , ARN Mensajero/metabolismo , Transcripción Genética , Factor de Necrosis Tumoral alfa/biosíntesisRESUMEN
We report an open-label study of 25 children with complex partial seizures that assessed the pharmacokinetics and safety of a single dose of approximately 0.1 mg/kg tiagabine. The children received their usual individualized regimen of one concomitant antiepilepsy drug (AED) throughout the study. Seventeen children were receiving an inducing AED (carbamazepine or phenytoin); eight were receiving valproate. Tiagabine was well tolerated. Dose-normalized Cmax was higher in children taking valproate (18.2 +/- 5.0 ng/mL/mg) than in the induced children (14.8 +/- 6.9 ng/mL/mg), but the difference was not statistically significant. Dose-normalized area under the plasma concentration-time curve from time zero to infinite time was significantly higher (p = 0.002) in children taking valproate (176.5 +/- 54.7 ng.hr/mL/mg) than in induced children (92.4 +/- 56.7 ng.hr/mL/mg). Similarly, oral clearance in the children taking valproate (96 +/- 39 mL/min) was half that of the induced children (207 +/- 91 mL/min). Half-life in children taking valproate (5.7 hr) was almost twice that for the induced children (3.2 hr), and the elimination rate constant was significantly lower (p < 0.02) for the children taking valproate than for the induced children. Volume of distribution was similar in the children taking valproate (52 +/- 9 L) and the induced children (59 +/- 29 L). This is consistent with observations in adults taking tiagabine with inducing AEDs or valproate. Exploratory regressions on these data in children and previous data in adults showed fairly strong relationships between body size and tiagabine clearance and volume of distribution, with body size explaining about 40 to 50% of the variability. When adjusted per kg body weight, clearance and volume were greater in children than adults. When adjusted per m2 body surface area, clearance and volume were more similar in adults and children.
Asunto(s)
Anticonvulsivantes/farmacocinética , Epilepsia Parcial Compleja/metabolismo , Ácidos Nipecóticos/farmacocinética , Anticonvulsivantes/administración & dosificación , Anticonvulsivantes/uso terapéutico , Constitución Corporal , Niño , Preescolar , Quimioterapia Combinada , Epilepsia Parcial Compleja/tratamiento farmacológico , Femenino , Humanos , Masculino , Ácidos Nipecóticos/administración & dosificación , Ácidos Nipecóticos/uso terapéutico , Fases del Sueño , Tiagabina , Ácido Valproico/uso terapéuticoRESUMEN
PURPOSE: To evaluate the pharmacokinetics and safety of multiple oral doses of tiagabine HCl in subjects with different degrees of hepatic impairment. METHODS: Four subjects with mild hepatic impairment, three subjects with moderate hepatic impairment, and six matched normal subjects received twice daily oral tiagabine HCl for 5.5 days. Serial blood specimens were obtained for 48 h after the final dose. Total and unbound tiagabine plasma concentrations were determined by high-performance liquid chromatography (HPLC) and ultrafiltration, respectively. Pharmacokinetic parameters were compared between the groups by analysis of covariance. RESULTS: For total tiagabine concentrations in normal subjects and subjects with mild and moderate hepatic impairment, C(max) values (mean +/- SD) were 117 +/- 54, 172 +/- 40, and 172 +/- 28 ng/ml; C(min) values were 13 +/- 4, 27 +/- 4, and 28 +/- 6 ng/ml; areas under the plasma concentration-time curve were 396 +/- 59, 633 +/- 16, and 675 +/- 32 ng x h/ml, and elimination half-lives (harmonic means) were 7, 12, and 16 h, respectively. Unbound tiagabine concentrations, area under the unbound plasma concentration-time curve, and the free fractions were increased in the hepatically impaired subjects. Reduced serum albumin and alpha1-acid glycoprotein concentrations may have contributed to increases in the unbound fraction. Adverse events observed included dizziness, tremor, nausea, somnolence, incoordination, and unsteady gait. The frequency of these events was increased in the subjects with liver impairment. CONCLUSIONS: Because of the decreased drug elimination caused by liver function impairment, reduced doses or increased dosing interval or both may be needed to attain therapeutic plasma drug concentrations. Time to reach steady state also may be prolonged. The patients should be monitored closely for potential neurologic adverse events.
Asunto(s)
Anticonvulsivantes/efectos adversos , Anticonvulsivantes/farmacocinética , Hepatopatías/metabolismo , Ácidos Nipecóticos/efectos adversos , Ácidos Nipecóticos/farmacocinética , Administración Oral , Adulto , Anciano , Anticonvulsivantes/sangre , Cromatografía Líquida de Alta Presión , Ritmo Circadiano , Creatinina/sangre , Relación Dosis-Respuesta a Droga , Femenino , Semivida , Humanos , Incidencia , Hepatopatías/sangre , Hepatopatías/diagnóstico , Masculino , Persona de Mediana Edad , Enfermedades del Sistema Nervioso/sangre , Enfermedades del Sistema Nervioso/inducido químicamente , Enfermedades del Sistema Nervioso/epidemiología , Examen Neurológico , Ácidos Nipecóticos/sangre , Albúmina Sérica/análisis , Índice de Severidad de la Enfermedad , Tiagabina , UltrafiltraciónRESUMEN
The autogenous veins of 17 dogs were distended with 40kPa, 80kPa and 120kPa pressure prior to grafting to femoral arteries respectively. The sections were harvested immediately, and after 1 week, 4 and 16 weeks and inspected with SEM. The endothelial cells of grafted veins were studied with an image analysis system. The results showed that the desquamation extent of intimal layer correlated positively with pressure. 80 and 120kPa caused relatively severe damage to the endothelium, which was significantly different from that of control group (P < 0.05). We conclude that preimplantation distention of vein grafts should be employed with less than 80kPa pressure, and 120kPa can never be used in clinic, as it adversely affects the course of reendotheli alization. The distention did not make a notable impact to graft patency rate as demonstrated in this experiment.
Asunto(s)
Endotelio Vascular/ultraestructura , Arteria Femoral/cirugía , Vena Femoral/trasplante , Animales , Perros , Femenino , Vena Femoral/ultraestructura , Procesamiento de Imagen Asistido por Computador , Masculino , Microscopía Electrónica de RastreoRESUMEN
Our study reveals that the earliest historical records of Sheng Mai Powder are found in "Yixue qiyuan" ("Origins of Medicine"), a medical book written by Zhang Yuansu and published in the beginning of 1186, 45 years earlier than the latest edition of "Neiwai shangbian huolun" ("Treaties on the identification of Internal Diseases and External Damages"), written by Li Gao in 1231. The study also suggests that the assertion of Sheng Mai Powder to be inaugurated by Sun Simiao is groundless.